Comment: SABCS 2014 Highlights

Comment: BOLERO-1 reports HER2-positive breast cancer latest PFS data

PD-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer

Combination of eribulin and capecitabine provides clinical benefit for women with metastatic breast cancer

Ovarian suppression with tamoxifen reduced recurrence for some women with premenopausal breast cancer

Comment: Impact of combined bevacizumab and presurgery chemo varies by subtype

High tumour immune cell levels may help screen HER2-positive breast cancer patients for chemo

CLL at ASH 2014: Expert discussion

Comment: Combining tamoxifen with ovarian suppression reduced recurrence of some breast cancers

BOLERO-1 reports HER2-positive breast cancer latest PFS data

Impact of adding bevacizumab to presurgery chemo for triple-negative breast cancer varies with subtype

Fulvestrant improves survival over anastrozole for patients with advanced breast cancer